Abstract:
Thirty subjects with arteriosclerotic vascular disease were treated
with 3 gram intravenous infusions of disodium ethylene diamine tetraacetic
acid (EDTA). These patients were evaluated objectively for both
right and left internal carotid atheromatous stenosis at the bifurcation,
before and after EDTA chelation. Each subject had treatments over
a period of approximately IO months. Overall intra-arterial obstruction
decreased 20.9% +/- 2.3% (t--g.921. p<.001*). Subjects with greater
than 33% (i.e. statistically + I i) above initial mean obstruction.
experienced a reduction in stenosis of 35.00% +/- 4.3% after treatment
(t-- S. 178, p<0.00 I * n= 16). (*Statistically significant change
comparing the difference of the means).
Introduction
This
continues a series of paper-s analyzing the effects of intravenous
ethylene diamine tetraacetic acid (EDTA) therapy (1-13). Many
physicians have successfully used EDTA to treat atherosclerotic
vascular disease (14-16). In particular, this research studied stenosis
at the bifurcation of the common carotid and in the internal carotid
arteries before and after EDTA infusions.
Conclusion
Significant
improvement in the treatment of carotid occlusive disease should
be as effective as surgery. The results from this study demonstrate
that EDTA chelation, together with appropriate nutritional supplements
and diet management can significantly decrease atheromatous plaque
and the chance of cerebral infarction, thus satisfying this requirement.
Moreover,
it should be emphasized that the safety of treatment, repeatedly
demonstrated in our studies (1-13), far outweighs the published
risks of endarterectomy (23). If the end result is equal to, or
better than surgery, chelation should be offered as the preferred
treatment.
Dr.
Rudolf practices and is a partner at the McDonagh Medical Center,
Inc. in Kansas City, Mo. were Dr. McDonagh is founder and Miss Barber
is Cardiac Director.
Address reprint requests to: Charles J. Rudolph, D.O., PhD.,
2800-A Kendalwood Pkwy, Kansas City, MO. 64119. (@1991 Human Science
Press, Inc. (complete studies on file)
Journal
of the National
Medical
Association. Vol 82, No 3
A
Pilot Double Blind Study of Sodium
Magnesium
EDTA in Peripheral Vascular Disease
Efrain
Olszewer, MD, had Calil Sabbag, MD, and James P. Caner, MD, Dr.
PH New Orleans, Louisiana
Ten male patients with peripheral vascular disease, Type 2 (LaFontaine),
were randomly assigned in a double-blind study to receive either
Na2 ethylene diamine tetra acetic acid (EDTA) plus MgSO4, B complex,
and vitamin C, or a placebo of MgSO4, B complex, and vitamin C in
Ringer's lactate solution. A total of 20 intravenous infusions were
planned for administration to each patient. Clinical and laboratory
(noninvasive) tests showed dramatic improvements after 10 infusions
in some patients, thus was broken the code indicating who receiving
EDTA and who was receiving
placebo. The group that
improved had been receiving EDTA; there was no change in the placebo
group. The trial was then completed in single-blind fashion. Patients
originally assigned to receive placebo then received IO EDTA infusions,
while the group originally assigned to EDTA received 20 EDTA infusions.
The group that had formerly received placebo showed improvements
comparable to those
seen in the first EDTA group after 10 treatments.
To
our knowledge, no one has yet published a double-blind study evaluating
the effectiveness ofNaMg
EDTA in the treatment of peripheral vascular disease. Some case
reports and retrospective studies, including our recent review of
2870 cases of chronic degenerative disease treated with EDTA have
been published.2-5 We, therefore, conducted a pilot double blind
clinical trial of EDTA in peripheral vascular disease.
METHODOLOGY
Ten
patients, all male, with a mean age of 47 years (range 41 to 53),
and all with peripheral vascular disease from diabetes or arteriosclerosis,
aggravated by smoking, were enrolled in the study. They were all
stage 2 of the LaFontaine Classification, which means that they
had intermittent claudication, but no pain at activity, at rest,
or in the night and no gangrene. They included eight former heavy
cigarette smokers, all of whom had quit at least 6 months before
the study began.
From
CEWO, Sac) Paulo, Brazil', an affiliate of the International Institute
of Preventive Medicine, Rua Tamadi 320. Perdizes. 05002 Sao Paulo,
Brazil. Requests for reprints should be addressed to Dr. James P.
Carter, Tulane Univ. School of Public Heath and Tropical Medicine,
1501 Canal Street. suite 809. New Orleans. LA. 70112.
EDTA
Chelation Therapy in theTreatment
of Vascular Disease
Ethylenediamine
tetraacetic acid EDTA) chelation therapy has been used for decades
for the treatment of vascular disease, alone or in combination with
other treatments. This article includes a historical review of the
research literature, current evidence of effectiveness, potential
mechanisms of action EDTA, and some brief case reports. The authors
conclude that EDTA Chelation therapy is a valuable therapeutic option
for vascular disease, either alone or in conjunction with standard
treatment protocols. Key words : angina, atherosclerosis, chelation,
claudication , EDTA, vascular disease.
Chelation
is defined as the incorporation of a metal ion into a heterocyclic
ring structure. Living systems, use chelates commonly, for example,
in many enzyme functions and in the structure and function of heme
(a chelate of iron) and chlorophyll (a chelate of magnesium). Ethylenediamine
tetraacetic acid (EDTA) is a synthetic amino acid with chelating
properties. It was first used clinically for the treatment of lead
toxicity before 1950 and was reportedly used for control of hyper-calcemia
in 1950.
It
was noted that patients being treated with EDTA for lead toxicity
reported improvement, apparently coincidentally, in angina pectoris.
That observation began
the
investigation of the use of EDTA in the treatment of atherosclerotic
vascular disease. As a result, the first study of the use of EDTA
in atherosclerotic disease was published in 1956. Clarke, et al
2 reported on the results of chelation therapy in 20 patients with
confirmed diseases 19 of whom improved as measured by physical activity.
They stated "A placebo action seemed improbable for several
reasons. There was slight if any clinical improvement until after
the discomfort of 20, and with a few, 30 infusions. A patient's
progress was based on measured physical activity rather than appraisal
of subjective Symptoms. The improvement gained has been retained
and expanded in all, and a few for as long as 2 years, The results
have been uniformly good.
L..
Terry Chappell, MD Private Practice Bluffton, Ohio
Assistant
Professor of Family Practice Wright State School of Medicine Dayton,
Ohio
President-Elect
of the American College for Advancement in Medicine
Michael
Janson, MD Private Practice
Barnstable,
Massachusetts, Chairman of the Scientific Advisory Committee, Program
Chairman of the American College for Advancement In Medicine President
of America Preventive Medical Association.
Benefits
of EDTA Chelation Therapy in Arteriosclerosis: A Retrospective Study
of 470 Patients.
C.
Hancke, M.D, and K. Flytlie, M.D.
Abstract: In a retrospective study we report results of EDTA chelation in 470
patients, using a number of parameters, most of them objective.
Although the patients acted as their own controls, we observed improvements
of8O to 91%, depending on the measurement used. Of 92 patients referred
for surgical intervention, only 10 required ultimate surgery after
or during their chelation therapy, thus saving an estimated 3 million
dollars of insurance money. Our experience covers a period of 6
years and we saw no severe side effects or casualties arising from
the treatment. We conclude that EDTA chelation therapy is safe effective
and cost saving.
Introduction:
Intravenous
administration of ethylene diamine tetraacetic acid (EDTA) has been
used from the beginning of the 1950's by an increasing number of
physicians throughout the world for the treatment of arteriosclerosis.
In the last few years, there has been increasing criticism
of surgical intervention in this disease, since it falls to prolong
life, and is a temporary solution in treating a generalized, chronic
condition (1). In addition, surgery damages vital tissue by means
of reperfusion-released free radical bursts (2,3). Effective- ness
of EDTA chelation therapy is cumulative over many years (4,90),
and the recent association of iron in the etiology of cardiovascular
disease (IO) makes the technique worthy of complete acceptance today.
Claus
Hancke, M.D. received his medical education at the University of
Copenhagen. He is in general practice and is the president of the
Danish Chelation Doctors. He is an ABCT diplomat.
Knut
Flytlie, M.D. received his medical education at the University of
Gutenberg, Germany. He is in general practice and operates a clinic
for Preventive Medicine and Chelation. He is an ABCT diplomat.
Address
correspondence to Claus Hancke, M. D.,Hovedgade 17, 1, DK- 2800-LYNGBY,
Denmark. Additional information may be obtained from ACAM. Phone
number on contents page.
*In
our view, the beneficial results that were observed were far in
excess of the 10-15% improvement that is usually seen in the placebo
group of a controlled study. Of 65 patients who were referred for
coronary by-pass surgery, 58 did not require it after chelation
therapy.
